These findings imply that dual GRPR/NTS1R-targeting of prostate cancer may increase the diagnostic sensitivity of pathological lesions using suitable cocktails of bombesin (BBN, Pyr-Gln-Arg-Leu-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2)- and neurotensin (NT, pyr-Glu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu-OH)-based analogs. This evidence concerns the gene GRP and Familial prostate cancer.